Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate02 adjuvant saruparib in BRCA-mutated high-risk localized prostate cancer
2024-513586-39-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Saruparib arm with Placebo arm (2 arms). Primary endpoint: Metastasis-free survival by standard clinical imaging or PSMA-PET. Planned start Dec 2025; status: authorised.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-513586-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513586-39-00.